Hepion Pharmaceuticals Appoints Dr. Kaouthar Lbiati as CEO with Compensation Tied to $3M Equity Financing
HEPA sits 82% above its 52-week low of $0.033 on light trading volume (0.2× avg).
Summary
Hepion Pharmaceuticals appointed Dr. Kaouthar Lbiati as CEO, whose compensation includes deferred salary contingent on securing a minimum $3 million equity financing, signaling a critical need for capital and new strategic direction.
Key Events · Executive and Board Changes · HEPA
-
New CEO Appointment
Dr. Kaouthar Lbiati was appointed Chief Executive Officer, effective January 8, 2026.
-
Compensation Structure
Dr. Lbiati will receive an annual base salary of $350,000 and a target annual cash bonus of 35% of her base salary.
-
Financing Incentive
$50,000 of her base salary is deferred and payable upon the successful completion of an equity financing of at least $3,000,000.
-
Change of Control Bonus
A bonus of 3.0% of Enterprise Value is accrued if a Change of Control occurs with an Enterprise Value of at least $5,000,000.
Analysis · HEPA · Life Sciences
The appointment of Dr. Kaouthar Lbiati as CEO signals a new leadership direction for Hepion Pharmaceuticals. Her compensation structure, particularly the deferred salary contingent on a minimum $3 million equity financing, highlights the company's critical need for capital and incentivizes the new CEO to secure it. For a company of this size, successful financing is paramount for continued operations and drug development. Investors will be watching for updates on this financing and the new CEO's strategic initiatives.
How filings like this one have moved
In the 30 days to Oct 3, 2026, 28.9% of the 1666 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HEPA was trading at $0.06 on OTC in the Life Sciences sector, with a market capitalization of approximately $697.2K. The 52-week trading range was $0.03 to $1,325.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.